Skip to content
Triangle logo TriangleGet started
← Carcinosarcoma

NCT04513665 · STUDY IN CONTEXT

ZW25 in Women With Endometrial Cancers

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

ORR = Compete Response (CR) + Partial Response (PR) by RECIST v 1.1 \</= 24 weeks from the start of treatment

No participants accrued to Stage 2 arm

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-carcinosarcoma
nct id
NCT04513665
trial label
ZW25 in Women With Endometrial Cancers
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
1
harms Count
2
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-carcinosarcoma
    nct id
    NCT04513665
    outcome key
    om-0000
    source section id
    NCT04513665-om-0000
    source outcome index
    0
    endpoint
    Overall Response Rate/ORR of Participants
    endpoint definition
    ORR = Compete Response (CR) + Partial Response (PR) by RECIST v 1.1 \</= 24 weeks from the start of treatment
    time origin
    </= 24 weeks from the start of treatment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    No participants accrued to Stage 2 arm
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-carcinosarcoma
    nct id
    NCT04513665
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Stage 1
    regimen
    Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants. ZW25: ZW25 at 20mg/kg intravenously (IV) every two weeks.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT04513665-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-carcinosarcoma
    nct id
    NCT04513665
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Stage 2
    regimen
    If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. ZW25: ZW25 at 20mg/kg intravenously (IV) every two weeks.
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT04513665-om-0000#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-carcinosarcoma
    nct id
    NCT04513665
    harm key
    EG000
    source section id
    NCT04513665-ae
    event group key
    EG000
    event group label
    Stage 1
    serious affected
    2
    serious at risk
    16
    other affected
    16
    other at risk
    16
    frequency threshold
    0
    collection period
    24 weeks from end of treatment, up to 48 weeks
    event definition
    No participants accrued to Stage 2 arm
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-carcinosarcoma
    nct id
    NCT04513665
    harm key
    EG001
    source section id
    NCT04513665-ae
    event group key
    EG001
    event group label
    Stage 2
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    24 weeks from end of treatment, up to 48 weeks
    event definition
    No participants accrued to Stage 2 arm
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice